The Albert Einstein College of Medicine wishes to continue its participation in the scientific and educational activities of the Eastern Cooperative Oncology Group (ECOG). The College has continued to accrue patients to ECOG studies at a satisfactory rate. Recent tabulations indicate increased accrual by the College to both group-wide and approved pilot studies. From February 4, 1983 through February 3, 1984 the College enrolled 80 new patients on group-wide studies and 46 on approved pilot studies. Most pilot studies to which College patients accrued were conceived of and chaired or co-chaired by an Einstein investigator. It is expected that accrual to multimodality studies will increase at the College, primarily due to the appointment of a new Chairman of Radiation Oncology with extensive cooperative group experience. In addition, the network of collaborating affiliate institutions of the College ECOG program has recently enlarged with the addition of institutions in New Jersey and Westchester County. The goals of this project during the next funding period are 1) to increase total accrual to ECOG studies by 15 percent, 2) to increase participation by the College in multimodality ECOG trials, 3) to continue to add new collaborators to the affiliate network of the College, and 4) to improve the timeliness of data submission by the College to ECOG by appointing additional data management personnel.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA014958-14
Application #
3556289
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-06-01
Project End
1989-04-30
Budget Start
1988-05-01
Budget End
1989-04-30
Support Year
14
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Albert Einstein College of Medicine
Department
Type
Schools of Medicine
DUNS #
009095365
City
Bronx
State
NY
Country
United States
Zip Code
10461
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Erbe, Amy K; Wang, Wei; Goldberg, Jacob et al. (2017) FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clin Cancer Res 23:2159-2168
Smith, M R; Hong, F; Li, H et al. (2017) Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia 31:517-519
Schneider, Bryan P; Shen, Fei; Jiang, Guanglong et al. (2017) Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103. JCO Precis Oncol 2017:
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726
Sanchez-Martin, Marta; Ambesi-Impiombato, Alberto; Qin, Yue et al. (2017) Synergistic antileukemic therapies in NOTCH1-induced T-ALL. Proc Natl Acad Sci U S A 114:2006-2011
Roberts, Kathryn G; Gu, Zhaohui; Payne-Turner, Debbie et al. (2017) High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol 35:394-401
Perez Horta, Zulmarie; Goldberg, Jacob L; Sondel, Paul M (2016) Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy. Immunotherapy 8:1097-117
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Wilson, Melissa A; Zhao, Fengmin; Khare, Sanika et al. (2016) Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res 22:374-82

Showing the most recent 10 out of 146 publications